Therapeutic options in peripheral T cell lymphoma

Area of Science:

• Hematology
• Oncology
• Lymphoma Research

Background:

• Peripheral T cell lymphoma (PTCL) is a rare, aggressive non-Hodgkin lymphoma with poor survival rates.
• Current first-line treatments for PTCL are largely ineffective, leading to rapid relapse in most patients.
• Existing 5-year overall survival rates for PTCL range from 10% to 30%.

Purpose of the Study:

• To review current treatment approaches for PTCL.
• To emphasize emerging novel agents and combination therapies for PTCL management.
• To discuss the potential role of stem cell transplantation in PTCL treatment.

Main Methods:

• Literature review of retrospective and prospective studies on PTCL treatments.
• Identification and summarization of novel therapeutic agents and combinations.
• Analysis of current and investigational treatment strategies for PTCL.

Main Results:

• Several novel agents show promise, including histone deacetylase inhibitors, immunoconjugates, antifolates, monoclonal antibodies, and kinase inhibitors.
• Combination therapies involving agents like bendamustine and L-asparaginase are being explored.
• Stem cell transplantation is considered an important therapeutic option.

Conclusions:

• Novel targeted therapies and combination chemotherapies are crucial for improving PTCL outcomes.
• Emerging treatments offer hope for better patient survival and disease control.
• A comprehensive approach integrating new agents and transplantation may enhance PTCL management.